SUMMARY Complement activation may play an important role in the pathogenesis of coeliac disease. In the present study immunohistochemical localisation of C3 and of a neoantigen exposed only on the terminal C5b-9 complement complex has been performed on small intestinal biopsy sections from newly diagnosed untreated coeliac patients, from coeliac patients on long-term glutenfree diet and from disease controls. Levels of C3 were markedly increased in treated coeliac patients compared with controls. Staining of C3 was concentrated subepithelially and within the centre of the lamina propria. No staining was detected at these sites using antibody to the neoantigen, however, strongly suggesting that the increased levels of C3 seen in the coeliac patients was the result of increased extravasation of serum proteins rather than complement activation. Surprisingly, complement activation was detected within the glands of Brunner. Positive staining using anti-C5b-9 neoantigen was found in all coeliac patients, both treated and untreated.
Although the pathogenic mechanism in coeliac disease is not yet fully understood, involvement of the immune system is generally accepted. Antibody,'-complement,`T cell,"'"' and mast cell" responses at the site of disease activity have all been reported but the relative contribution of each of these factors remains unclear. Evidence for participation of complement in the disease process comes from the finding of reduced levels of serum concentrations of some complement components4 and from immunohistochemical localisation of large quantities of complement within the coeliac small bowel.;-It is not known, however, whether the complement detected in the coeliac intestine is activated, and therefore involved in damaging processes, or is present in native form, simply as a result of increased \ddre'ss for correspeo.ulmdcc I)r RKli.elrd B Ga. extravasation of serum proteins. In this study we have addressed this question by using a monoclonal antibody which detects a neoantigen exposed only on formation of the terminal C5b-9 complex. Thus complement activation in the coeliac small bowel, through either classical or alternate pathway, is detectable using this antibody.
Methods SMALL INTESTINAI, BIOPSIES
Intestinal biopsies, taken at endoscopy from the distal duodenum, were obtained from 10 coeliac patients and 13 disease controls. Five of the coeliac patients were newly diagnosed, with characteristic histological abnormalities which showed improvement on subsequent gluten free diet. The other five coeliac patients were on longterm gluten free diet (Table 1 ). The diagnosis of the 13 disease controls are shown in Table 2 . The tissues were embedded in Complementt activation within the coeliac sinall i/itestinie is localise(l to Brunner's glalld16s (hastric ulcer 7 Antral gastritis 8
Nornial-1. 9 Nornial against the C5b-9 ncoanitigen' were also used. In these cases binding was assessed by peroxidase labelled swine antirabbit immunoglobulin, diluted 1/20.
The quantity of C3 present in the tissue was examined using rabbit antihuman C3c sera (Dakopatts, Denmark) diluted 1/60, followed by peroxidase conjugated swine antirabbit Ig (Dakopatts) diluted 1/40. Anti-C3c antisera detects an epitope present on native C3, on C3b and on C3c.
After counterstaining in haematoxylin and mounting, the sections were randomised and assessed by an independent observer. Figure 2 . It can be seen that C3 is present in each of the three groups and the intensity of staining follows the pattern found withini the lamina propria; most intense in the untreated coeliac group, intermediate in the treated coeliac group, and least intense in the control group.
Examination of staining by the monoclonal antibody to the neoantigen of the C5b-9 complex revealed a distinct and uniique selectivity for the glands of Brunner in coeliac patients ( Fig. 3 and   1570 Table 3 ). In all 10 biopsies from coeliac patients neoantigen was detected within the glands. The intensity of staining varied and was assigned as being either strong (Fig. 3a) or weak (Fig. 3b) . The extent of staining was also variable, though in each case between one third and two thirds of all lobules of the gland were affected. Of the 12 disease controls examined three had evidence of complement activation, one staining strongly (patient no 6, Table 2 ) and two weakly (patients 8 and 13, Table 2 ).
Using the polyclonal antisera to the complement neoantigens on a limited number of samples, identical findings to those for the monoclonal antibody were obtained (results not shown).
Discussion
The two major findings of this report are that (i) there is no activation of complement within either the epithelial or lamina propria compartments of the coeliac small intestine and (ii) complement activation, exquisitely restricted to the glands of Brunner, is detectable in coeliac patients.
The involvement of complement in the disease process was proposed a number of years ago on the basis of immunohistochemical staining showing C3 deposition in conjunction with IgA (5) In this study we have repeated C3 staining in the coeliac lamina propria and obtained results con1-sistent with previous studies, namely that there is a quantitative increase in the amounit of C3 withini the coeliac lamina propria. Resolution of the questionl of' whether or not this compiement is activated was made possible by the development of monooclonal and polyclonal antibodies against neoantigens present only on the activated C5b-9 compiemenit complex. Using such reagenits we have shown that 1O complement activation occurs eithier subepithelially or within the lamina propria in the coeliac mucosa despite the larger increase in concentration of C3. This strongly suggests that compiemeiit activation plays no part in the disease process at these sites and accumulates by non-specific mechanisms.
Complement activation was, however, detectable at a different site in coeliac biopsies: all 10 patients examined had deposition of the C5b-9 complex within the glands of Brunner. In contrast, complement activation at this site was found in only three of 12 disease controls.
Brunner's glands are located in the submucosa of the duodenum, being most numerous in the proximal portion. Interestingly, the mucosal abnormalities of coeliac disease are also most marked in the proximal duodenum.-Brunner's glands have been shown to secrete mucus, bicarbonate and epidermal growth factor (EGF), agents which are important in mucosal defence and repair processes.' Thus complementmediated attack on these glands may seriously compromise mucosal defence by interfering with secretion of these factors. This possibility is currently under investigation.
Deposition of the terminal complement complex occurs within Brunner's gland, not only in untreated coeliac patients but also in patients on long term gluten free diet in whom marked clinical and histological improvement has been noted. This suggests that continuing complement activation occurs in spite of strict adherence to gluten free diet. An alternative explanation is that the complement was deposited while the patients were still on gluten containing diet. This is very unlikely as the half life of terminal complement complexes on the surface of nucleated cells is measured in minutes. '4 At present there is no obvious explanation for the finding of complement activation in three of the controls with no apparent duodenal abnormalities. In two of these staining was very faint but in the third it was strong.
The pathway by which the complement is activated within the Brunner's glands remains to be elucidated. Possible mechanisms include (i) entrapment of immune complexes within the gland with subsequent activation of the classical pathway, (ii) deposition of a complement activating autoantibody, and (iii) alternate pathway activation. Immune complexes have been described in the circulation of patients with coeliac disease, including those on gluten free diet, and in the majority of cases they can fix complement.4 Sequestration of these complexes within the Brunner's glands is therefore potentially important to the disease process. Unfortunately, at present, there is no information on the antibody or antigenic component of these complexes. An alternative explanation, that an autoantibody directed against an antigen on Brunner's gland is responsible for complement activation, is currently under investigation. Such an antibody would raise the possibility that coeliac disease, in common with many other HLA DR3-associated diseases, is initiated by a tissue specific autoimmune attack. Whatever the mechanism we are left with the intriguing possibility that damage to Brunner's gland leading to loss of mucosal defence and repair capability is an important factor in the development of gluten sensitive enteropathy. 
